
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is compelling because it combines a defensible CGM leadership position with expanding demand beyond intensive insulin users, supported by the CONNECT trial’s 6-month randomized data showing a −1.6% A1c reduction vs. −0.7% control, ~21% TIR improvement, and ~97% adherence in T2NIT patients. The consumer pivot is also strengthening the growth case: Stelo/NutriSense and the redesigned app show that meal logging, daily insights, coaching, and notifications can drive engagement more effectively than sensor readings alone, improving retention and utilization in broader OTC and non-intensive diabetes markets. Financially, DexCom’s 2026 revenue guidance of $5.16B-$5.25B, 63-64% adjusted gross margin, 22.2% adjusted operating margin, and $2.42B of cash support a scalable, profitable model with meaningful upside from CMS T2NIT coverage and 15-day rollout adoption.
Bears say
DexCom is facing a challenging fundamental setup because its growth depends on CGM penetration continuing to expand, yet competitive products could erode its moat and make sustained share gains harder to achieve. Regulatory hurdles may delay new product launches, while payor and CMS pricing pressure, combined with the high investment required to compete, could keep profitability difficult despite stable hardware performance and reliable alert functionality. The stock also appears vulnerable because it trades at a significant premium multiple, so any slowdown in adoption or weaker-than-expected product innovation could amplify downside risk.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares